Showing results (731-740 of 834) with videos related to

Sort By:
Pageof 84
Kidney International|September 24, 2021
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J L Heerspink, David Cherney, Douwe Postmus, et al.
Kidney Medicine|September 25, 2023
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY AnalysisSylvia E Rosas, Luis M Ruilope, Stefan D Anker, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 18, 2026
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW TrialKatherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer, et al.
Journal of the American College of Cardiology|September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 13, 2023
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysisGerasimos Filippatos, Stefan D Anker, Phyllis August, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 11, 2025
Protocol for a 1-year randomised, controlled, parallel group, open-label trial on the effects and feasibility of time-restricted eating in individuals with type 2 diabetes- The REStricted Eating Time in the treatment of type 2 diabetes (RESET2) trialAnne-Ditte Termannsen, Annemarie Varming, Natasja Bjerre, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trialDavid C Wheeler, Niels Jongs, Bergur V Stefansson, et al.
Kidney International|April 20, 2021
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathyDavid C Wheeler, Robert D Toto, Bergur V Stefánsson, et al.
Genes|May 27, 2023
Differential Methylation of Telomere-Related Genes Is Associated with Kidney Disease in Individuals with Type 1 DiabetesClaire Hill, Seamus Duffy, Laura M Kettyle, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Pageof 84